BIM
ABUS icon

Bogle Investment Management’s Arbutus Biopharma ABUS Stock Holding History

Bogle Investment Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-41,700
Closed -$131K – 148
2020
Q3 		$131K Buy
+41,700
New +$127K 0.04% 219
2014
Q3 		– Sell
-240,006
Closed -$3.13M – 347
2014
Q2 		$3.13M Sell
240,006
-150,660
-39% -$2.14M 0.21% 135
2014
Q1 		$8.39M Buy
390,666
+294,769
+307% +$5.3M 0.58% 71
2013
Q4 		$764K Buy
+95,897
New +$799K 0.06% 246

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bogle Investment Management's ABUS Position: Q4 2020 in Review

Bogle Investment Management sold out of Arbutus Biopharma (ABUS) in Q4 2020, closing a stake of 41,700 shares — an estimated $131K sold.

Bogle Investment Management first reported a position in ABUS in Q4 2013 and held it in 4 quarters. The position peaked at $8.39M in Q1 2014. 80 funds tracked by Wall St. Rank hold ABUS as of Q4 2020.

  • Bogle Investment Management reported no remaining Arbutus Biopharma position as of Q4 2020 after selling out during the quarter.
  • Bogle Investment Management sold 41,700 Arbutus Biopharma shares in Q4 2020, an estimated $131K.
  • Bogle Investment Management first reported a position in Arbutus Biopharma in Q4 2013 and held it in 4 quarters.
  • Bogle Investment Management's Arbutus Biopharma position peaked at $8.39M in Q1 2014.
  • 80 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2020.

Based on Bogle Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.